Review of Recent Outpatient Therapeutic Updates for SARS-Cov2 |Biomedgrid

While great strides have been made within the medical community to combat the spread, mortality, and morbidity of SARS-CoV-2, there remains need for identifying effective therapeutics given the ever-evolving nature of the virus. Given the growing number of variants, it is important that medical providers are up to date on the most recent evidence-based therapeutics for the management of SARS-CoV-2. Fortunately, the progress in antivirals and monoclonal antibodies have demonstrated success as outpatient therapeutics for patients at-risk for poor disease outcomes. This article reviews therapeutics approved for outpatient management of SARS-CoV-2 in conjunction with the recently updated guidelines from the World Health Organization, Infectious Disease Society of America, National Institutes of Health, and United States Food and Drug Administration. Monoclonal antibodies Casirivimab plus Imdevimab and Bamlanivimab plus Etesevimab are no longer recommended as a therapeutic for the Omicron variant. Paxlovid, an antiviral, and Sotrovimab, a monoclonal antibody, are considered the therapy of choice for at-risk patients. Remdesivir is considered a reasonable alternative but has intravenous limitations. Molnupiravir is only indicated should all other approved therapeutics be either unavailable or contraindicated.